- About UsOur Story, Our Team & Support Information
- What We DoAdvocacy to Achieve the End of AIDS
- Advance HIV/SRH Integration
- Advocate for Access to High-Impact Prevention
- Improve Research Conduct
- Product Innovation & Availability
- Promote Effective HIV Prevention Policy
- Strengthen Global Advocacy Networks
- Track and Translate the Field
- Our FocusInterventions to End the Epidemic
- ResourcesPublications, Infographics, Events & More
- MediaInformation & Resources for the Press
- Our BlogPrevention News & Perspective
Status
Completed
Phase
I
Principal Investigator(s)
Jill Schwartz
Objective
To evaluate the interaction of TFV gel, antifungal cream, antimicrobial gel and a contraceptive ring.
Prevention Option(s)
Hormonal Contraceptives and HIV
Microbicides
Study Design
Randomized
Open label
Arms and Assigned Interventions
Description
Tenofovir gel only
Mode of Delivery
Gel
Products
1% tenofovir gel
ARMs
Experimental
Description
Vaginal products & tenofovir gel: tenofovir gel, antifungal cream, antimicrobial gel, contraceptive ring
Mode of Delivery
Gel
Ring
Products
1% tenofovir gel
Contraceptive Vaginal Ring
Metronidazole
Terconazole
ARMs
Experimental
Description
Vaginal products only: antifungal cream, antimicrobial gel, aontraceptive ring
Mode of Delivery
Gel
Ring
Products
Contraceptive Vaginal Ring
Metronidazole
Terconazole
ARMs
Experimental
Official Code
Trial Sponsors
CONRAD
December 2013
December 2014
Enrollment
54
18
Years
50
Years
Population
Women
Sites
Bronx-Lebanon Hospital
New York, New York
United States of America
University of California
San Francisco, California
United States of America